EFTR
Effector Therapeutics Inc
NASDAQ: EFTR · HEALTHCARE · BIOTECHNOLOGY
$0.00
+0.00% today
Updated 2026-04-30
Market cap
$940.00
P/E ratio
—
P/S ratio
69.65x
EPS (TTM)
$-12.57
Dividend yield
—
52W range
$0 – $0
Volume
0.0M
Effector Therapeutics Inc (EFTR) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | — | $42.00M | $1.43M | $3.55M | $0.00 |
| Revenue growth (YoY) | — | — | -96.6% | +148.5% | -100.0% |
| Cost of revenue | $307000.00 | $160000.00 | $24000.00 | $53000.00 | $111000.00 |
| Gross profit | $-307000.00 | $42.00M | $1.43M | $3.50M | $-111000.00 |
| Gross margin | — | 100.0% | 100.0% | 98.5% | — |
| R&D | $23.58M | $21.83M | $19.96M | $23.31M | $22.92M |
| SG&A | $4.71M | $4.35M | $13.37M | $12.64M | $10.93M |
| Operating income | $-28.61M | $15.82M | $-31.90M | $-32.40M | $-33.84M |
| Operating margin | — | 37.7% | -2230.6% | -912.0% | — |
| EBITDA | $-28.05M | $16.05M | $-31.87M | $-32.35M | $-32.78M |
| EBITDA margin | — | 38.2% | -2228.9% | -910.5% | — |
| EBIT | $-28.36M | $15.89M | $-31.90M | $-32.40M | $-32.89M |
| Interest expense | $1.38M | $1.33M | $1.76M | $2.25M | $2.92M |
| Income tax | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-29.74M | $14.21M | $15.80M | $-12.93M | $-35.81M |
| Net income growth (YoY) | — | +147.8% | +11.2% | -181.8% | -177.0% |
| Profit margin | — | 33.8% | 1104.8% | -363.8% | — |